Multiple sclerosis is currently an incurable, chronic autoimmune disease. While it is possible to effectively manage the feared relapses with existing therapies, novel approaches aim to provide important protection against long-term impairments.
Since 1995, the Eppendorf Award for Young European Investigators, endowed with €20,000, has honored outstanding achievements in the field of biomedical research in Europe once a year.
Dutch Forbion has announced its largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2bn and Forbion Ventures Fund VII raising €890m.
Lundbeck A/S is set to take over all shares of neurology specialist Longboard Pharmaceuticals Inc worth US$2.6bn to strengthen its pipeline with the Phase III 5-hydroxythyprytamaine 2C receptor super-agonist bexicaserine to treat 11 rare neurological conditions.
https://european-biotechnology.com/wp-content/uploads/2024/10/Lundbecks-headquarters-in-Valby-e1728977732319.jpeg7211280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-10-15 09:36:572024-10-15 09:36:57Lundbeck to take over Longboard Pharma in US$2.6bn transaction
German diagnostics company Sphingotec GmbH has licensed its real-time kidney function test to US diagnostics giant Beckman Coulter allowing it to expand its business to the US as announced earlier this month.
https://european-biotechnology.com/wp-content/uploads/2024/08/PenkidMOA.png326554Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-10-09 10:57:572024-10-09 11:00:09Sphingotec licenses kidney function test
Biomanufacturers must balance the development of new therapeutic modalities and reduce manufacturing costs while maintaining environmental responsibility. Efforts are centred on improving process robustness and efficiency and creating more flexible manufacturing facilities that can accommodate diverse biopharmaceutical products.
https://european-biotechnology.com/wp-content/uploads/2024/09/F3_Enhanced-mAb-capturing.jpg540960Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2024-10-09 08:00:212024-09-26 10:42:25Ensuring sustainability and continuity in biomanufacturing
AviadoBio Ltd has cashed in €30m upfront and €20m as an equity investment from Astellas Pharma Inc for signing a licence option agreement for its Phase I/II gene therapy programme AVR-01.
Swedish clinical-stage pharmaceutical company Vicore Pharma has secured SEK100m, supported by existing and new investors. The injection of capital will allow the company to scale the clinical development of its portfolio of therapies in respiratory and fibrotic diseases.
https://european-biotechnology.com/wp-content/uploads/2024/10/lung-freepik-ai-20241008.jpeg6751200Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2024-10-08 14:45:282024-10-08 14:45:28Vicore secures funding to accelerate drug development
Fab’entech, a French biopharma company, has secured a loan worth €20m from the European Investment Bank (EIB) under the HERA Invest programme, aimed at bolstering Europe’s preparedness against biological threats.
https://european-biotechnology.com/wp-content/uploads/2024/04/Scotland.jpg7681280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-10-03 09:25:302024-10-03 09:25:50Kurma closes new fund at €250m
Focus on long-term protection
Sponsored PublicationsMultiple sclerosis is currently an incurable, chronic autoimmune disease. While it is possible to effectively manage the feared relapses with existing therapies, novel approaches aim to provide important protection against long-term impairments.
Eppendorf Award 2025: Apply now!
Sponsored PublicationsSince 1995, the Eppendorf Award for Young European Investigators, endowed with €20,000, has honored outstanding achievements in the field of biomedical research in Europe once a year.
Forbion raises more than €2bn for two new funds
Latest NewsDutch Forbion has announced its largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2bn and Forbion Ventures Fund VII raising €890m.
Lundbeck to take over Longboard Pharma in US$2.6bn transaction
Latest NewsLundbeck A/S is set to take over all shares of neurology specialist Longboard Pharmaceuticals Inc worth US$2.6bn to strengthen its pipeline with the Phase III 5-hydroxythyprytamaine 2C receptor super-agonist bexicaserine to treat 11 rare neurological conditions.
Sphingotec licenses kidney function test
Latest NewsGerman diagnostics company Sphingotec GmbH has licensed its real-time kidney function test to US diagnostics giant Beckman Coulter allowing it to expand its business to the US as announced earlier this month.
Ensuring sustainability and continuity in biomanufacturing
Sponsored PublicationsBiomanufacturers must balance the development of new therapeutic modalities and reduce manufacturing costs while maintaining environmental responsibility. Efforts are centred on improving process robustness and efficiency and creating more flexible manufacturing facilities that can accommodate diverse biopharmaceutical products.
AviadoBio Ltd inks US$2.2bn gene therapy deal with Astellas Pharma Inc
Latest NewsAviadoBio Ltd has cashed in €30m upfront and €20m as an equity investment from Astellas Pharma Inc for signing a licence option agreement for its Phase I/II gene therapy programme AVR-01.
Vicore secures funding to accelerate drug development
Latest NewsSwedish clinical-stage pharmaceutical company Vicore Pharma has secured SEK100m, supported by existing and new investors. The injection of capital will allow the company to scale the clinical development of its portfolio of therapies in respiratory and fibrotic diseases.
€20m loan for pandemic preparedness
Latest NewsFab’entech, a French biopharma company, has secured a loan worth €20m from the European Investment Bank (EIB) under the HERA Invest programme, aimed at bolstering Europe’s preparedness against biological threats.
Kurma closes new fund at €250m
Latest NewsKurma Partners announced a first closing of its new Biofund IV at €140m targeted to raise €250m to finance 16-20 life science companies.